Revolutionizing Healthcare: The Pharmacy Market

 Pharmacy Industry Overview

The global pharmacy market size was estimated at USD 1.26 trillion in 2023 and is expected to grow at a CAGR of 7.28% from 2024 to 2030. The growing demand for specialty drugs globally and increasing prescription drug expenditure in developed countries are expected to drive the growth of the market over the forecast period. In addition, the growing prevalence of chronic diseases, majorly due to changes in lifestyle and a rapidly aging population, are supplementing the market growth.

The growing demand for prescription medications is contributing to the industry's growth. As the demand for prescription drugs increases, pharmacies experience a surge in business due to the need for dispensing these medications. According to the National Health Service the current cost of an NHS prescription in England for 2024-2025 is USD 12.65 per item, an increase of USD 0.51 from the previous year. Prescription charges are usually reviewed annually. The cost has increased steadily in recent years, from USD 8.80 in 2015 - 2016 to USD 10.47 in 2024 - 2025.

Gather more insights about the market drivers, restrains and growth of the Pharmacy Market

The growing demand for prescription medications is contributing to the industry's growth. As the demand for prescription drugs increases, pharmacies experience a surge in business due to the need for dispensing these medications. According to the National Health Service the current cost of an NHS prescription in England for 2024-2025 is USD 12.65 per item, an increase of USD 0.51 from the previous year. Prescription charges are usually reviewed annually. The cost has increased steadily in recent years, from USD 8.80 in 2015 - 2016 to USD 10.47 in 2024 - 2025.

Moreover, pharmacies are adopting digitalization programs to cater to the growing demand from consumers and provide improved accessibility to patients. For instance, CVS Health introduced a Digital Transformation program to personalize the healthcare experience using artificial intelligence, machine learning, data, and analytics. Moreover, in December 2021, the company entered into a partnership with Microsoft to scale up retail personalization and loyalty programs using advanced machine learning, powered by Azure. Such digitalization and automation strategies are anticipated to drive the growth in the industry during the forecast period. 

Pharmacy Market Segmentation

Grand View Research has segmented the global pharmacy market report based on product, type, and region.

Pharmacy Product Outlook (Revenue, USD Billion, 2018 - 2030)

• Prescription
• OTC

Pharmacy Type Outlook (Revenue, USD Billion, 2018 - 2030)

• Hospital Pharmacy
• Retail Pharmacy
o Chain
o Independent
o Others
• ePharmacy
• Others

Pharmacy Regional Outlook (Revenue, USD Billion, 2018 - 2030)

• North America
o U.S.
o Canada
o Mexico
• Europe
o UK
o Germany
o France
o Italy
o Spain
o Sweden
o Denmark
o Norway
• Asia Pacific
o Japan
o China
o India
o Australia
o Thailand
o South Korea
• Latin America
o Brazil
o Argentina
• MEA
o South Africa
o Saudi Arabia
o UAE
o Kuwait

Browse through Grand View Research's Pharmaceuticals Industry Research Reports.

• The global connective tissue disease market size was estimated at USD 24.04 billion in 2023 and is expected to grow at a CAGR of 6.1% from 2024 to 2030. This growth is attributed to the increasing prevalence of these diseases, advancements in diagnostic techniques & treatment approaches, and growing demand for effective treatments.

• The global clinical nutrition for diabetes care market size was estimated at USD 2.15 billion in 2023 and is expected to register a CAGR of 4.78% from 2024 to 2030. The increasing demand for specialized food products by individuals with diabetes or those at risk of developing the condition is a critical factor for the diabetes clinical nutrition market growth.

Key Companies profiled:

• CVS Health
• Boots Walgreens
• Cigna
• Walmart
• Kroger
• Rite Aid Corp.
• Lloyd Pharmacy
• Well Pharmacy
• Humana Pharmacy Solutions
• Matsumoto Kiyoshi
• Apollo Pharmacy
• MedPlusMart.com

About Grand View Research

Grand View Research, U.S.-based market research and consulting company, provides syndicated as well as customized research reports and consulting services. Registered in California and headquartered in San Francisco, the company comprises over 425 analysts and consultants, adding more than 1200 market research reports to its vast database each year. These reports offer in-depth analysis on 46 industries across 25 major countries worldwide. With the help of an interactive market intelligence platform, Grand View Research Helps Fortune 500 companies and renowned academic institutes understand the global and regional business environment and gauge the opportunities that lie ahead.

Order a free sample PDF of the Pharmacy Market Intelligence Study, published by Grand View Research.

Deciphering Molecules with NMR: Principles and Applications

 Nuclear Magnetic Resonance Spectroscopy Industry Overview

The global nuclear magnetic resonance spectroscopy market size was estimated at USD 760.71 million in 2023 and is projected to grow at a CAGR of 5.1% from 2024 to 2030. The market growth is attributed to the increasing funding & investment initiatives for nuclear magnetic resonance (NMR) spectroscopy in biomedical research, the rising need for affordable generic medicines, the growing scope of NMR spectroscopy in non-healthcare sectors, and the rising adoption of the technique in medical diagnosis.

NMR spectroscopy is considered an effective method to assess crystalline & amorphous pharmaceuticals in the drug and its product. Hence, the development of generic drugs is expected to boost the requirement for NMR spectroscopy. Moreover, the presence of universities, product developers, and pharmaceutical companies’ service providers drives the growth. The essential processes in the pharmaceutical industry are the characterization of drug substances, identifying the structure of crystalline, and observing form conversion during Active Pharmaceutical Ingredient (API) scale-up. Solid-state NMR spectroscopy is considered an analytical tool for investigating multiple crystalline forms in an API and a drug product. Hence, the demand for NMR spectroscopy is anticipated to increase significantly with growing drug development activities.

Gather more insights about the market drivers, restrains and growth of the Nuclear Magnetic Resonance Spectroscopy Market

NMR spectroscopy is advancing its presence in diagnostics through biomedical research, such as studying peptides, proteins, nucleic acids, and amino acids. The technique can analyze the dynamics, structure, and interactions of macromolecules. Hence, increasing research in the biomedical field is anticipated to enhance the use of spectroscopy. According to a report published by WHO in February 2023, the number of funders and their contribution to biomedical research has been growing since 2012. In 2020, approximately 74,702 grants were allotted for biomedical research. The National Institutes of Health contributed the largest grants out of the total granted amount for biomedical research. Hence, the increasing number of grants for biomedical research is anticipated to drive the demand for NMR spectroscopy due to its wide use in biomedical research.

Moreover, several studies have demonstrated promising results for using NMR in metabolomics diagnosis. For instance, a study published by Dove Press in March 2022 reported that serum metabolites can serve as potential diagnostic biomarkers for tumor metastasis. H-NMR spectroscopy was utilized in this study to investigate serum metabolic profiles in a mouse model of colorectal cancer with lung metastasis. Moreover, according to a study published by Intech Open Ltd in February 2018, NMR-based metabolomics contributes to lung cancer diagnosis, even in the early phases of tumor development. Hence, rising metabolomics-based diagnosis for various conditions, such as lung cancer, is anticipated to drive the demand over the forecast period.

Furthermore, the diagnosis of Parkinson’s disease, cancer, & infectious and psychiatric disorders has been investigated using NMR spectroscopy. Various companies and academic participants are focusing on metabolomics-based diagnosis using NMR. For instance, in January 2022, the University of Oxford developed a new blood test using NMR metabolomics to identify various cancers. According to an article published by GenomeWeb in October 2021, Lifespin, a metabolomics testing firm, used NMR to develop metabolomics-based diagnostics. The company reported that its scientists had developed NMR-based metabolomic profiles of around 130,000 people, spanning a variety of disorder cohorts, which can help them develop a metabolomics-based diagnosis. Hence, the increasing focus of leading players and academic institutions on NMR for metabolomics diagnosis is anticipated to drive market growth over the forecast period.

However, the high cost of the equipment is anticipated to be a restraining factor for the market's growth.The superconducting nature of magnets increases the cost of this technique. According to the study published by Aston University in September 2023, the cost of large high-field NMR spectrometry instruments can range from USD 0.72 million to USD 12.1 million. Furthermore, the need to regularly supply high-field magnets with cryogenic fluids (He and N2) and the routine hardware maintenance of electronics & probes make this technique expensive. In addition, the highly specialized staff is required to operate NMR spectroscopy equipment, which may boost the cost associated with using this technique.

Browse through Grand View Research's Biotechnology Industry Research Reports.

• The global peptide microarray market size was valued at USD 288.3 million in 2023 and is projected to grow at a CAGR of 6.18% from 2024 to 2030. The growing burden of chronic diseases, technological advancements in diagnostic testing, and rising adoption of peptide microarrays are some of the factors that drive market growth.

• The global rare cell isolation market size was estimated at USD 1.83 billion in 2023 and is projected to grow at a CAGR of 9.71% from 2024 to 2030. The market has been experiencing significant growth, driven by advancements in biotechnology and the increasing need for precision medicine.

Nuclear Magnetic Resonance Spectroscopy Market Segmentation

Grand View Research has segmented the global nuclear magnetic resonance spectroscopy market report based on product, type, end use and region.

Nuclear Magnetic Resonance Spectroscopy Product Outlook (Revenue, USD Million, 2018 - 2030)

• Instruments
• Consumables

Nuclear Magnetic Resonance Spectroscopy Type Outlook (Revenue, USD Million, 2018 - 2030)

• Low-field NMR Spectroscopy
• High-field NMR Spectroscopy

Nuclear Magnetic Resonance Spectroscopy End-use Outlook (Revenue, USD Million, 2018 - 2030)

• Academic
• Pharmaceutical and Biotech Companies
• Agriculture and Food
• Chemical Industry
• Others

Nuclear Magnetic Resonance Spectroscopy Regional Outlook (Revenue, USD Million, 2018 - 2030)

• North America
o U.S.
o Canada
• Europe
o UK
o Germany
o France
o Italy
o Spain
o Denmark
o Sweden
o Norway
• Asia Pacific
o Japan
o China
o India
o South Korea
o Australia
o Singapore
o Thailand
• Latin America
o Brazil
o Mexico
o Argentina
• Middle East & Africa
o South Africa
o Saudi Arabia
o UAE
o Kuwait

Key Companies profiled:

• JEOL Ltd.
• Thermo Fisher Scientific Inc.
• Bruker
• Magritek
• Oxford Instruments
• Nanalysis Corp.
• Anasazi Instruments, Inc.
• QoneTec
• Advanced Magnetic Resonance Limited

Order a free sample PDF of the Nuclear Magnetic Resonance Spectroscopy Market Intelligence Study, published by Grand View Research.

Recent Developments

• In April 2024, Bruker Corporation unveiled new magnet technology and analytical solutions to enhance the adoption in academic research, clinical studies, and biopharma drug discovery, development, and Process Analytical Technologies (PAT).

• In December 2023, Bruker Corporation successfully installed a 1.2 GHz NMR system at Ohio State University’s National Gateway Ultrahigh Field NMR Center. This advanced system would significantly enhance the center’s research capabilities, enabling groundbreaking studies in structural biology, materials science, and related fields by providing unprecedented resolution and sensitivity.

• In May 2023, JEOL Ltd. published a paper focusing on an innovative method to determine the mutual orientation of two hydrogens in solid-state NMR. This paper was developed in collaboration with IIT Ropar and Lowa State University. Such publications help researchers and increase awareness about the company’s products during their studies.

 

Condom Market Insights: Consumer Behavior and Preferences

 Condom Industry Overview

The global condom market size was estimated at USD 11.59 billion in 2023 and is expected to grow at a CAGR of 8.72% from 2024 to 2030. The increase in awareness regarding the use of condoms, measures to reduce the spread of HIV & other Sexually Transmitted Infections (STIs), and the availability of different types of products to suit consumer needs are likely to drive market growth during the forecast period.

According to the World Health Organization (WHO) in 2023, approximately 374 million new cases of syphilis, gonorrhea, chlamydia, and trichomoniasis were reported annually. In the same year, WHO reported that 39.0 million people were living with HIV globally, with two-thirds of them residing in the African countries. This can lead to serious complications beyond the immediate effect of the infection itself. If left untreated, STDs can lead to complications such as impotence and infertility. According to a study published on Factors associated with adverse pregnancy outcomes of maternal syphilis in Henan, China, 2016-2022, in 2016, around 1 million pregnant women were detected with active syphilis, which resulted in 200,000 stillbirths and 350,000 adverse birth outcomes. This is expected to boost demand for the use of condoms during the forecast period.

Gather more insights about the market drivers, restrains and growth of the Condom Market

Several companies in the market are currently involved in merger and acquisition activities. These companies want to expand their reach and explore new territories through M&A deals. For instance, in December 2022, Linden Capital Partners acquired LifeStyles Healthcare, a global sexual health and wellness platform, from a consortium of investors, including Humanwell Healthcare and Trustar Capital. It is a significant acquisition for Linden, a Chicago-based private equity firm focusing exclusively on the healthcare industry.

Condoms are highly regulated in the U.S. and are classified as Class II medical devices by the U.S. FDA. These Class II medical devices have to comply with specific performance and labeling standards. As per the FDA standards, 996 out of 1,000 condoms should pass the water leak test to receive FDA approval, which accounts for at least a 99.6% efficacy rate in laboratory tests. Latex condom manufacturing and testing are governed by FDA regulations with stringent standards.
Companies are focusing on developing novel product designs to attract consumers, such as condoms with innovative flavors, textures, and lubricants. For example, flavored products designed for oral sex aim to enhance the user experience and increase demand.

The condom industry is growing globally due to its potential to improve accessibility, cost-effectiveness, and outcomes. This growth is fueled by established industry leaders expanding into emerging marketplace and indigenous startups experiencing growth. Companies are expanding by launching facilities or plants in new geographies merging with or acquiring companies based in different locations. For example, in May 2023, Church & Dwight Co. Inc. expanded its operations at the Trojan Condom Plant in southeastern Chesterfield.

Browse through Grand View Research's Medical Devices Industry Research Reports.

• The global laparoscopic retrieval bag market size was estimated at USD 382.60 million in 2023 and is projected to expand at a CAGR of 6.98% from 2024 to 2030. The growth can be attributed to the growing focus on patient safety during complex surgical procedures and increasing prevalence of lifestyle-related chronic conditions, including gastrointestinal disorders, urological disorders, & cancer.

• The global smart inhalers market size was estimated at USD 15.4 billion in 2023 and is expected to expand at a CAGR of 19.4% from 2024 to 2030. The rising prevalence of chronic respiratory diseases (CRDs) globally, the development of technologically advanced products, and the growing adoption of digital solutions in the healthcare sector are expected to contribute to the market's growth.

Condom Market Segmentation

Grand View Research has segmented the global condom market report based on material type, product, distribution channel, and region:

Condom Market Material Type Outlook (Revenue, USD Million, 2018 - 2030)

• Latex Condoms
• Non-latex Condoms
o Polyurethane and Polyisoprene
o Lambskin
o Nitrile Butadiene Rubber (NBR)

Condom Market Product Outlook (Revenue, USD Million, 2018 - 2030)

• Male Condoms
• Female Condoms

Condom Market Distribution Channel Outlook (Revenue, USD Million, 2018 - 2030)

• Public Health Distribution
• Drug Stores
• E-commerce
• Mass Merchandizers

Condom Market Regional Outlook (Volume in ‘000; Revenue, USD Million, 2018 - 2030)

• North America
o U.S.
o Canada
• Europe
o UK
o Germany
o France
o Italy
o Spain
o Sweden
o Denmark
o Norway
• Asia Pacific
o Japan
o China
o India
o Australia
o Thailand
o South Korea
• Latin America
o Brazil
o Mexico
o Argentina
• MEA
o South Africa
o Saudi Arabia
o UAE
o Kuwait
o Nigeria
o Kenya
o Zambia
o Zimbabwe
o Uganda
o Egypt
o Turkey
o Ghana

Key Companies profiled:

• FUJILATEX CO.,LTD
• Reckitt Benckiser Group PLC
• Church & Dwight Co., Inc.
• Karex Berhad
• LELO iAB
• Lifestyles
• Veru Inc.
• Okamoto Industries, Inc
• MAYER LABORATORIES, INC.
• Cupid Limited
• RITEX GMBH
• Pasante Healthcare Ltd.
• CPR GmbH
• Mankind Pharma
• Sagami Rubber Industries Co., Ltd.
• rrtMedcon

Order a free sample PDF of the Condom Market Intelligence Study, published by Grand View Research.

Recent Developments

• In April 2023, Veru Inc. has entered into a Purchasing Agreement with Afaxys Group Services, LLC (AGS) to offer Veru’s FC2 Female Condom (internal condom) through the AGS Group Purchasing Organization (GPO). This agreement will benefit up to 31 million women and men who depend on community & public health centers for essential healthcare.

• In May 2021, SKYN, the leading sexual wellness brand and maker of the nonlatex condom, has launched SKYN Excitation, a new condom with a unique wave design featuring raised dots on the most sensitive areas. This new product is set to enhance the sexual experience for those who use it.

 

Unlocking Growth Opportunities in the ENT Devices Market

 ENT Devices Industry Overview

The global ENT devices market size was estimated at USD 25.93 billion in 2023 and is expected to grow at a compound annual growth rate (CAGR) of 5.54% from 2024 to 2030. This growth can be attributed to several factors, such as high prevalence of ENT-related disorders, an increase in the usage of minimally invasive ENT procedures and rising geriatric population. Technological advancements also play a crucial role in driving the market growth.

The demand for advanced ENT devices, like robot-assisted endoscopes, is more in developed countries such as the U.S. while it is less in developing countries due to their high cost. The ENT devices market penetration is anticipated to grow significantly due to increasing healthcare spending by other governments and a rise in per capita income. Sales are expected to increase rapidly in developing economies due to high occurrences of ENT diseases such as hearing loss and sinusitis. Additionally, there is an increase in efforts to provide better access to healthcare facilities in these regions.

Gather more insights about the market drivers, restrains and growth of the ENT Devices Market

Hearing loss or impairment is a common condition among patients, particularly in industrialized countries. The World Health Organization reported, more than 430 million people worldwide, approximately 5% of the world's population, have a disabling hearing loss. This number is projected to rise to over 700 million, or one in every ten people, by 2050. The main reasons for this increase are growing life expectancy and noise pollution, leading to more age-related hearing loss cases. In low-income countries, infections such as middle ear infections, measles, or meningitis are the common causes of hearing loss. Moreover, vascular disorders, noise exposure, chronic inflammation, genetic susceptibility, physiological aging of the ear contributing to hearing impairment.

Rising technological advancements such as the adoption of AI and ML and innovations in auditory products are propelling industry growth. For instance, in September 2023, ELEHEAR Inc., an AI-powered hearing aids and audio solutions provider, introduced ELEHEAR Alpha Pro and ELEHEAR Alpha hearing aid devices. It is incorporated with AI noise reduction and extraction, which predicts daily users and their actions to minimize the effect of noise in typical audio environments such as public transit, offices, restaurants, homes, and busy streets. In March 2023, Oticon Medical A/S introduced new features in the processing chip Polaris R, which uses an onboard Deep Neural Network (DNN) for an entirely new method of sound processing. The updated processing chip features include sudden sound stabilizer and Wind & Handling Stabilizer.

Browse through Grand View Research's Medical Devices Industry Research Reports.

• The global pediatric cardiac surgery market size was estimated at USD 15.6 billion in 2023 and is projected to grow at a CAGR of 9.8% from 2024 to 2030. The market’s growth is primarily driven by the rising incidence of congenital heart defects and heart failure in children.

• The global hybrid imaging market size was valued at USD 7.91 billion in 2023 and is projected to grow at a CAGR of 6.1% from 2024 to 2030. This market is primarily driven by the increasing significance of integration of molecular and anatomical data & standalone imaging techniques, and the rising cases of chronic disorders worldwide.

ENT Devices Market Segmentation

Grand View Research has segmented the global ENT devices market report based on product and region:

ENT Devices Product Outlook (Revenue, USD Million, 2018 - 2030)

• Diagnostic ENT Devices
o Rigid Endoscopes
o Sinuscopes
o Otoscopes
o Laryngoscopes
o Flexible Endoscopes
o Bronchoscopes
o Laryngoscopes
o Nasopharyngoscopes
o Robot Assisted Endoscope
o Hearing Screening Device
• Surgical ENT Devices
o Radiofrequency handpieces
o Otological Drill Burrs
o ENT Hand Instruments
o Sinus Dilation Devices
o Nasal Packing Devices
• Hearing Aids
• Hearing Implants
• Nasal Splints

ENT Devices Regional Outlook (Revenue, USD Million, 2018 - 2030)

• North America
o U.S.
o Canada
• Europe
o U.K.
o Germany
o France
o Italy
o Spain
o Denmark
o Sweden
o Norway
• Asia Pacific
o China
o Japan
o India
o South Korea
o Australia
o Thailand
• Latin America
o Brazil
o Mexico
o Argentina
• Middle East & Africa (MEA)
o South Africa
o Saudi Arabia
o UAE
o Kuwait

Key Companies profiled:

• Ambu A/S
• Cochlear Ltd.
• Demant A/S
• GN Store Nord A/S
• Karl Storz SE & Co.
• Olympus Corporation
• Pentax of America, Inc.
• Richard Wolf GmbH
• Rion Co., Ltd.
• Smith & Nephew plc
• Sonova
• Starkey Laboratories, Inc.
• Stryker
• Nico Corporation
• Nemera

Key ENT Devices Company Insights

Some of the key market players include, Cochlear Ltd., Demant A/S, Stryker, and KARL STORZ.

• Cochlear Ltd. (Cochlear) engages in developing and commercializing cochlear implants, bone conduction implants, & acoustic implants to treat hearing-impaired individuals. Cochlear Ltd. is a global company with major manufacturing facilities in Sweden and Australia.It has a global presence in more than 180 countries.

• Demant A/S (Demant) is a global company that develops, manufactures, and commercializes hearing implants, traditional hearing instruments, personal communication devices, & diagnostic instruments. The group operates in over 30 countries and sells its products in over 130 countries.

 

Order a free sample PDF of the ENT Devices Market Intelligence Study, published by Grand View Research.

Recent Developments

• In April 2023, Unitron, a brand of Sonova launched Vivante, a platform aimed to enhance listener’s experience through personalized hearing control. This platform offers improved sound performance and new designs to enhance the hearing experience, integrating experience innovations and the remote plus app to offer a customized hearing experience.
• In February 2023, Cochlear Ltd. announced a partnership with Amazon.com, Inc. to expand audio streaming for hearing aids for people with Cochlear's hearing implants to provide comfortable entertainment.

• In November 2022, Cochlear Ltd. announced the expansion of its manufacturing facility plant in Kuala Lumpur, Malaysia. The expansion involved an asset of more than USD 6.28 million (RM 30 million) to help the growing demand for acoustic and cochlear hearing implants.

Fueling Innovation: The Small Molecule Innovator CDMO Landscape

 Small Molecule Innovator CDMO Market Industry Overview

The global small molecule innovator CDMO market size was estimated at USD 48.6 billion in 2023 and is expected to expand at a compound annual growth rate (CAGR) of 6.21% from 2024 to 2030. Key drivers for this growth are increasing pharmaceutical R&D investment, growing demand for small molecules, and rising incidence of cancer & age-related disorders. Biological drugs are more expensive than small molecules. Hence, growing demand for cost-effective drugs is expected to further support market growth.

The COVID-19 pandemic significantly impacted on global economy in 2020 and caused an ongoing impact on various industries. However, the market for contract development and manufacturing organization (CDMO) witnessed a positive impact due to this pandemic. CDMOs played an important role in meeting the needs of pharmaceutical companies, biotech companies, and other end-users during this crisis. Overall, pandemic boosted market demand for small molecule innovator drugs. With the growing demand for outsourcing by pharma companies, heightened demand is observed in post-pandemic scenario.

Gather more insights about the market drivers, restrains and growth of the Small Molecule Innovator CDMO Market

Small Molecule Innovator CDMO Market Segmentation

Grand View Research has segmented the global small molecule innovator CDMO market based on application and region:

Small Molecule Innovator CDMO Product Outlook (Revenue, USD Million, 2018 - 2030)
• Small Molecule API
• Small Molecule Drug Product
o Oral solid dose
o Semi-Solid Dose
o Liquid Dose
o Others

Small Molecule Innovator CDMO Stage Type Outlook (Revenue, USD Million, 2018 - 2030)
• Preclinical
• Clinical
o Phase I
o Small
o Medium
o Large
o Phase II
o Small
o Medium
o Large
o Phase III
o Small
o Medium
o Large
• Commercial

Small Molecule Innovator CDMO Customer Type Outlook (Revenue, USD Million, 2018 - 2030)
• Pharmaceutical
o Small
o Medium
o Large
• Biotechnology

Small Molecule Innovator CDMO Therapeutic Area Outlook (Revenue, USD Million, 2018 - 2030)
• Cardiovascular disease
• Oncology
• Respiratory disorders
• Neurology
• Metabolic disorders
• Infectious disease
• Others

Small Molecule Innovator CDMO Regional Outlook (Revenue, USD Million, 2018 - 2030)
• North America
o U.S.
o Canada
• Europe
o U.K.
o Germany
o France
o Italy
o Spain
o Denmark
o Sweden
o Norway
• Asia Pacific
o India
o Japan
o China
o Australia
o South Korea
o Thailand
• Latin America
o Brazil
o Mexico
o Argentina
• Middle East & Africa
o South Africa
o Saudi Arabia
o UAE
o Kuwait

Browse through Grand View Research's Medical Devices Industry Research Reports:

• The global large molecule drug substance CDMO market size was valued at USD 11.5 billion in 2022 and is expected to expand at a compound annual growth rate (CAGR) of 9.3% from 2023 to 2030.
• The global sterile injectables CDMO market size was estimated at USD 3.94 billion in 2023 and is projected to grow at a CAGR of 9.92% from 2024 to 2030.

Key Companies profiled:
• Piramal Pharma Solutions
• CordenPharma International
• Wuxi AppTec
• Cambrex Corporation
• Recipharm AB
• Pantheon (Thermo Fisher Scientific)
• Lonza
• Catalent Inc.
• Siegfried Holding AG
• Boehringer Ingelheim
• Labcorp Drug Development

Key Small Molecule Innovator CDMO Company Insights

Key parameters affecting the competitive nature of the market include acquisition, geographic expansion, mergers, acquisitions, and product launches.

• In September 2022, WuXi STA inaugurated a new sterile lipid nanoparticle (LNP) formulation development and manufacturing facility at its Wuxi city campus. The integrated drug product platform CRDMO provides a full range of services, including solid-state development, pre-formulation, and clinical to commercial drug product manufacturing.
• In June 2022, Lonza inaugurated a new clinical phase development and manufacturing facility in its small molecules site in Bend, Oregon. It is dedicated to manufacturing bioavailability-enhancing spray-dried dispersion (SDD) finished dosage forms and drug product intermediates.

Order a free sample PDF of the Small Molecule Innovator CDMO Market Intelligence Study, published by Grand View Research.

About Grand View Research

Grand View Research, U.S.-based market research and consulting company, provides syndicated as well as customized research reports and consulting services. Registered in California and headquartered in San Francisco, the company comprises over 425 analysts and consultants, adding more than 1200 market research reports to its vast database each year. These reports offer in-depth analysis on 46 industries across 25 major countries worldwide. With the help of an interactive market intelligence platform, Grand View Research Helps Fortune 500 companies and renowned academic institutes understand the global and regional business environment and gauge the opportunities that lie ahead.

Contact:

Sherry James

Corporate Sales Specialist, USA

Grand View Research, Inc.

Phone: 1-415-349-0058

Toll Free: 1-888-202-9519

Email: sales@grandviewresearch.com

Web: https://www.grandviewresearch.com

Follow Us: LinkedIn | Twitter

The Biopharmaceuticals Contract Manufacturing Market: A Comprehensive Analysis

Biopharmaceuticals Contract Manufacturing Industry Overview

The global biopharmaceuticals contract manufacturing market was valued at USD 17.0 billion in 2021 and is projected to grow at a compound annual growth rate (CAGR) of 5.2% during the forecast period. The success of the biopharmaceutical market can be majorly attributed to the contract manufacturers. Reduction in the overall investment required to bring a new drug product to market, providing access to expensive technologies, quick entry of products into the markets, and greater flexibility are some advantages offered by contract manufacturing organizations (CMOs), which have prompted the companies to outsource their biopharmaceutical manufacturing.

Due to the disruptions from COVID-19, many companies have had to bring on new contract manufacturers or ingredient suppliers due to increasing demands. Furthermore, with a perpetual expansion of the biopharmaceutical industry, the companies are facing production issues, such as lack of expertise and sophisticated equipment, while practicing in-house manufacturing. The maturity of biotechnology and the availability of external funding have resulted in the growth in a number of early-stage bio/pharma companies. These companies are recognized as core customers of CMOs, as these organizations lack the capabilities for the development of robust manufacturing operations.

Gather more insights about the market drivers, restrains and growth of the Biopharmaceuticals Contract Manufacturing Market

In order to fulfill the growing demand in the market, key players are going for capacity expansion. For instance, in 2020, Thermo Fisher Scientific announced an investment of USD 180.0 million for the construction of a new commercial manufacturing site in Plainville, Mass for viral vector development and manufacturing services. Also, in 2019, Boehringer Ingelheim invested USD 84 million for expansion in Mexico for increasing production. The customers and CMOs are engaged in standardizing agreement terms for making contract negotiations easy. This is to address the issues pertaining to the regulatory landscape and complexity of service delivery. IP rights, warranty & liabilities, prices & timelines are major issues cited by CMOs and clients which are making negotiations innately difficult.

Breakthrough technological advancements and innovations in bioprocessing have played a pivotal role in the progress of contract service providers by overcoming the manufacturing issues such as high production costs and the need for changeover with every batch. Single-use bioprocessing systems are one of the most significant innovations as it helps in reducing the overall production and scale-up costs. Furthermore, the fast turnaround offered by single-use products while limiting allied activities, such as changeover and cleaning validation, has supported the growth of CMOs to a major extent.

Mergers, acquisitions, and joint ventures are one of the common trends observed across the industry, as it helps CMOs offer integrated bioprocessing services to their clients, which, in turn, makes them a more reliable option for a rapid product launch for commercial use. However, large firms consider outsourcing perilous due to loss of strategic control and limited management oversight. As a result, large pharma companies opt to maintain their manufacturing operations in-house. This is expected to challenge the growth of CMOs to a certain extent.

Browse through Grand View Research's Medical Devices Industry Research Reports.

• The global intrauterine devices market size was estimated at USD 6.25 billion in 2023 and is projected to grow at a CAGR of 3.66% from 2024 to 2030.
• The global dual chamber prefilled syringes market size was valued at USD 167.3 million in 2023 and is projected to grow at a CAGR of 5.8% from 2024 to 2030.

Biopharmaceuticals Contract Manufacturing Market Segmentation

Grand View Research has segmented the global biopharmaceuticals contract manufacturing market based on application and region:

Biopharmaceuticals Contract Manufacturing Source Outlook (Revenue, USD Million, 2017 - 2030)
• Mammalian
• Non-mammalian

Biopharmaceuticals Contract Manufacturing Service Outlook (Revenue, USD Million, 2017 - 2030)
• Process Development
o Downstream
o Upstream
• Fill & Finish Operations
• Analytical & QC studies
• Packaging

Biopharmaceuticals Contract Manufacturing Product Outlook (Revenue, USD Million, 2017 - 2030)
• Biologics
o Monoclonal antibodies (MABs)
o Recombinant Proteins
o Vaccines
o Antisense, RNAi, & Molecular Therapy
o Others
• Biosimilars

Biopharmaceuticals Contract Manufacturing Therapeutic Area Outlook (Revenue, USD Million, 2017 - 2030)
• Oncology
• Autoimmune Diseases
• Metabolic Diseases
• Cardiovascular Diseases
• Neurology
• Infectious Diseases
• Others

Biopharmaceuticals Contract Manufacturing Regional Outlook (Revenue, USD Million, 2017 - 2030)
• North America
o U.S.
o Canada
• Europe
o UK
o Germany
o France
o Italy
o Spain
• Asia Pacific
o China
o India
o Japan
o Australia
o South Korea
• Latin America
o Brazil
o Colombia
o Mexico
o Argentina
• Middle East & Africa
o South Africa
o Saudi Arabia
o UAE

Key Companies profiled:
• Boehringer Ingelheim GmbH
• Lonza
• Inno Biologics Sdn Bhd
• Rentschler Biotechnologie GmbH
• JRS PHARMA
• AGC Biologics
• ProBioGen
• FUJIFILM Diosynth Biotechnologies U.S.A., Inc.
• Toyobo Co. Ltd.
• Samsung BioLogics
• Thermo Fisher Scientific, Inc.
• Binex Co., Ltd.
• WuXi Biologics
• AbbVie, Inc.
• Novartis AG
• ADMA Biologics, Inc.
• Catalent, Inc
• Cambrex Corporation
• Pfizer Inc.
• Siegfried Holding AG

Order a free sample PDF of the Biopharmaceuticals Contract Manufacturing Market Intelligence Study, published by Grand View Research.

About Grand View Research

Grand View Research, U.S.-based market research and consulting company, provides syndicated as well as customized research reports and consulting services. Registered in California and headquartered in San Francisco, the company comprises over 425 analysts and consultants, adding more than 1200 market research reports to its vast database each year. These reports offer in-depth analysis on 46 industries across 25 major countries worldwide. With the help of an interactive market intelligence platform, Grand View Research Helps Fortune 500 companies and renowned academic institutes understand the global and regional business environment and gauge the opportunities that lie ahead.